Sandra Horning
Academic Appointments
- Emeritus Faculty, Acad Council, Medicine - Oncology
Key Documents
Contact Information
- Academic Offices
Personal Information EmailAlternate Contact Sarah Daadi Administrative Assistant Email Tel Work 650-725-6456
Professional Overview
Administrative Appointments
- President, ASCO (2005 - 2006)
- President-Elect, ASCO (2004 - 2005)
Honors and Awards
- Alwin C. Rambar-James B. D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2000)
Graduate & Fellowship Program Affiliations
Scientific Focus
Current Research Interests
The objectives of the clinical research program are:
1. to improve therapeutic outcomes and/or reduce complications of treatment, and
2. to further elucidate the underlying biology of Hodgkins disease (HD) and the non-Hodgkins lymphomas (NHL).
The research program is highly collaborative and includes ongoing clinical trials with myeloablative therapy in HD and NHL with the Bone Marrow Transplant team, combined modality trials in HD with Radiation Oncology, clinical-pathologic correlative studies with Pathology, and drug development with an emphasis on targeted therapy for B-cell lymphoma (anti-CD20) with industrial collaborators.
Dr. Horning is chairman of the Lymphoma Committee for the Eastern Cooperative Oncology Group, a forum for extending pilot studies to multi-institutional trials. Dr. Horning supervises a sophisticated multi-relational Lymphoma Database which has information on over 15,000 patients, an excellent resource for prospective and retrospective clinical investigations
Clinical Trials
- Recruiting Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
- Not Recruiting Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
- Recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
- Not Recruiting Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
- Not Recruiting A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Publications
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010; (4): 775-7; quiz 918
- Cancer research and privacy: the problem with being joined at the hip. J Clin Oncol. 2009; (24): 3879-80
- Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Am J Surg Pathol. 2009; (4): 591-8
- Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009; (10): 1607-14
- (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Hell J Nucl Med. 2008 Sep-Dec; (3): 153-6
- Follicular lymphoma, survival, and rituximab: is it time to declare victory? J Clin Oncol. 2008; (28): 4537-8
Help